Parametrica Management Ltd reduced its position in Humana Inc (NYSE:HUM) by 52.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 919 shares of the insurance provider’s stock after selling 1,031 shares during the period. Parametrica Management Ltd’s holdings in Humana were worth $229,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the company. WFG Advisors LP increased its position in shares of Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after acquiring an additional 20 shares in the last quarter. Scotia Capital Inc. increased its position in shares of Humana by 4.8% in the second quarter. Scotia Capital Inc. now owns 2,200 shares of the insurance provider’s stock worth $529,000 after acquiring an additional 100 shares in the last quarter. Advantus Capital Management Inc grew its position in Humana by 1.4% during the third quarter. Advantus Capital Management Inc now owns 14,798 shares of the insurance provider’s stock valued at $3,605,000 after purchasing an additional 203 shares in the last quarter. Cadence Capital Management LLC grew its position in Humana by 3.6% during the third quarter. Cadence Capital Management LLC now owns 5,887 shares of the insurance provider’s stock valued at $1,434,000 after purchasing an additional 205 shares in the last quarter. Finally, Daiwa SB Investments Ltd. grew its position in Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after purchasing an additional 220 shares in the last quarter. 94.39% of the stock is currently owned by institutional investors and hedge funds.
Shares of Humana Inc (NYSE HUM) opened at $267.10 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61. Humana Inc has a 1 year low of $189.01 and a 1 year high of $293.35. The company has a market cap of $39,500.82, a P/E ratio of 23.59, a price-to-earnings-growth ratio of 1.70 and a beta of 0.93.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. During the same period in the previous year, the company earned $3.18 earnings per share. Humana’s revenue for the quarter was down 3.0% on a year-over-year basis. sell-side analysts predict that Humana Inc will post 11.63 EPS for the current fiscal year.
Humana announced that its Board of Directors has authorized a share buyback program on Thursday, December 14th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the insurance provider to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.
In other news, VP Timothy S. Huval sold 1,382 shares of the business’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the completion of the sale, the vice president now directly owns 11,557 shares in the company, valued at $2,843,484.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jody L. Bilney sold 7,054 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the sale, the senior vice president now owns 11,704 shares of the company’s stock, valued at $2,901,304.56. The disclosure for this sale can be found here. Insiders sold 10,115 shares of company stock valued at $2,501,627 over the last 90 days. 0.80% of the stock is owned by corporate insiders.
HUM has been the topic of a number of research analyst reports. Credit Suisse Group lowered their price objective on shares of Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Jefferies Group reaffirmed a “hold” rating and set a $257.00 price objective on shares of Humana in a research report on Friday, October 13th. BMO Capital Markets boosted their price objective on shares of Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $242.00 price objective (down from $245.00) on shares of Humana in a research report on Thursday, November 9th. Nine research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $262.74.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thestockobserver.com/2018/02/06/parametrica-management-ltd-has-229000-stake-in-humana-inc-hum.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.